Want to see IN:MEDPLUS full AI Analyst Report?
MEDPLUS Stock Chart & Stats
₹808.80
₹1.40(0.17%)
At close: 4:00 PM EST
₹808.80
₹1.40(0.17%)
Day’s Range― - ―
52-Week Range₹731.95 - ₹1,020.35
Previous CloseN/A
Volume104.47K
Average Volume (3M)39.52K
Market Cap
₹97.84B
Enterprise Value₹113.19B
Total Cash (Recent Filing)₹4.62B
Total Debt (Recent Filing)₹14.24B
Price to Earnings (P/E)45.1
Beta0.50
Next Earnings
Aug 11, 2026EPS Estimate
2.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)18.33
Shares Outstanding120,137,060
10 Day Avg. Volume11,750
30 Day Avg. Volume39,524
Financial Highlights & Ratios
PEG Ratio1.00
Price to Book (P/B)5.10
Price to Sales (P/S)1.46
P/FCF Ratio24.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)20.63
Revenue Forecast (FY)₹77.71B
Bulls Say, Bears Say
Bulls Say
Omnichannel Retail ModelMedPlus's omnichannel network of neighborhood pharmacies plus digital ordering and home delivery creates durable customer convenience and loyalty. This distribution breadth supports recurring prescription volumes, cross-selling of OTC/wellness items, and logistics scale that underpin steady revenue and competitive positioning over 2–6 months and beyond.
Consistent Revenue Growth And Improved Cash FlowMulti-year revenue scaling coupled with materially improved operating and free cash flow in 2025–2026 provides a durable funding base for reinvestment. Stronger FCF supports store expansion, supply-chain investment and digital capabilities while reducing near-term financing reliance for growth initiatives.
Manageable Leverage And Improving ROEA balance sheet with growing equity, moderate debt-to-equity and an improving ROE (~11%) gives structural financial flexibility. Manageable leverage supports continued rollout and operating investment without immediate solvency pressure, enabling strategic execution while preserving capacity for shocks.
Bears Say
Thin And Volatile MarginsSustained net margins of roughly 1–3% and a sharp 2026 gross margin decline materially limit the firm's ability to convert sales into durable profits. Such a low-margin profile reduces buffers against cost inflation or competitive pricing, making long-term earnings and investment plans more sensitive to external shocks.
Rising Leverage TrendAn upward leverage trend since 2022 increases interest and refinancing exposure for a business with narrow margins. Greater debt reliance limits strategic optionality, raises break-even requirements for new stores or initiatives, and heightens the risk that earnings volatility forces margin-sacrificing measures to service debt.
Inconsistent Cash ConversionFCF at ~0.77x net income and uneven cash conversion across years indicate working-capital and reinvestment pressures. This inconsistency curtails the company's ability to self-fund expansion reliably, increases dependence on external financing for capex or store growth, and raises vulnerability during operational slowdowns.
MedPlus Health Services Ltd. News
MEDPLUS FAQ
What was MedPlus Health Services Ltd.’s price range in the past 12 months?
MedPlus Health Services Ltd. lowest stock price was ₹731.95 and its highest was ₹1020.35 in the past 12 months.
What is MedPlus Health Services Ltd.’s market cap?
MedPlus Health Services Ltd.’s market cap is ₹97.84B.
When is MedPlus Health Services Ltd.’s upcoming earnings report date?
MedPlus Health Services Ltd.’s upcoming earnings report date is Aug 11, 2026 which is in 30 days.
How were MedPlus Health Services Ltd.’s earnings last quarter?
MedPlus Health Services Ltd. released its earnings results on May 20, 2026. The company reported ₹5.3 earnings per share for the quarter, beating the consensus estimate of ₹5.2 by ₹0.1.
Is MedPlus Health Services Ltd. overvalued?
According to Wall Street analysts MedPlus Health Services Ltd.’s price is currently Overvalued.
Does MedPlus Health Services Ltd. pay dividends?
MedPlus Health Services Ltd. does not currently pay dividends.
What is MedPlus Health Services Ltd.’s EPS estimate?
MedPlus Health Services Ltd.’s EPS estimate is 2.2.
How many shares outstanding does MedPlus Health Services Ltd. have?
MedPlus Health Services Ltd. has 120,137,060 shares outstanding.
What happened to MedPlus Health Services Ltd.’s price movement after its last earnings report?
MedPlus Health Services Ltd. reported an EPS of ₹5.3 in its last earnings report, beating expectations of ₹5.2. Following the earnings report the stock price went down -1.974%.
Which hedge fund is a major shareholder of MedPlus Health Services Ltd.?
Currently, no hedge funds are holding shares in IN:MEDPLUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedPlus Health Services Ltd.
MedPlus Health Services Limited operates primarily as an Indian retailer of pharmaceutical products and diverse general merchandise. Its extensive product catalog includes vital health and wellness items such as prescription medications, vitamins, medical equipment, and diagnostic kits, alongside everyday essentials like toiletries, baby care products, cleaning supplies, and sanitizers. Beyond its retail footprint, the company also offers wholesale cash-and-carry services, comprehensive pathological laboratory testing, and contract manufacturing for its own-brand pharmaceutical goods. By March 31, 2021, MedPlus had established a substantial presence with 1,659 brick-and-mortar stores situated in the Indian states of Karnataka, Tamil Nadu, Telangana, and Andhra Pradesh, complemented by its online store. This Hyderabad-based company was incorporated in 2006.
Technical Analysis
Krsnaa Diagnostics Limited
―
Dr. Lal PathLabs Limited
―
Metropolis Healthcare Ltd.
―
Sastasundar Ventures Limited
―
Thyrocare Technologies Ltd
―